Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose cytarabine and idarubicin for adult acute lymphoblastic leukaemia
ACTRN12615000631505Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jun 2002
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine, idarubicin and methotrexate in acute lymphoblastic leukemia (ALL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Induction death rate and Grade 3 and 4 non-haematological toxicities. Started Jun 2002; status: completed.
02
Drugs
cytarabineidarubicinmethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12615000631505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000631505.